MOTS-c typical research dosing
Across the available literature, MOTS-c is most commonly administered at 5000–10000 mcg per dose, 1 time(s) per day, via subcutaneous injection. Research has used 5–10 mg subcutaneously 2–3× per week. Human pharmacokinetic data is limited.
MOTS-c unit-conversion table
The number of insulin-syringe units you draw depends on how much bacteriostatic water you used to reconstitute the vial. The table below shows units to draw on a U-100 syringe for a 10 mg MOTS-c vial at common reconstitution volumes.
| Diluent (mL) | Concentration | 5000 mcg | 7500 mcg | 10000 mcg |
|---|---|---|---|---|
| 1 mL | 10000 mcg/mL | 50.0 units | 75.0 units | 100.0 units |
| 2 mL | 5000 mcg/mL | 100.0 units | 150.0 units | 200.0 units |
| 3 mL | 3333 mcg/mL | 150.0 units | 225.0 units | 300.0 units |
| 5 mL | 2000 mcg/mL | 250.0 units | 375.0 units | 500.0 units |
MOTS-c cycle length
Most reported MOTS-c protocols run 4 weeks on, then 2 weeks off. Cycles are used in research to study washout, receptor sensitivity, and to re-baseline endogenous signaling before re-introducing the compound.
MOTS-c half-life and timing
MOTS-c has a half-life of approximately 3 hours. This influences dose frequency: shorter half-lives often require multiple doses per day to maintain steady-state levels, while longer half-lives can be dosed less frequently.